老虎證券

BUZZ-H.C. Wainwright starts coverage of Galectin Therapeutics with 'buy'

Reuters
06-17
BUZZ-H.C. Wainwright starts coverage of Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> with 'buy'

** H.C. Wainwright initiates coverage of drug developer Galectin Therapeutics GALT.O with 'buy' rating; sets PT at $6, which is ~233.3% upside on stock's last close

** Brokerage says Galectin is currently developing belapectin to treat chronic liver disease called metabolic dysfunction-associated steatohepatitis (MASH), which can progress to cirrhosis, liver failure and liver cancer

** H.C. Wainwright says GALT's belapectin is only therapy in development for MASH cirrhosis

** "Initial clinical trials exhibited compelling trends towards preventing and halting signs and symptoms of the disease," brokerage says

** Including session's moves, stock up ~45% YTD

(Reporting by Prakhar Srivastava in Bengaluru)

((Prakhar.srivastava2@thomsonreuters.com))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10